Kintara Therapeutics Debt 2024

Kintara Therapeutics Aktienanalyse

What does Kintara Therapeutics do?

Kintara Therapeutics Inc is a US-based biosciences company specializing in the development of cancer drugs and other clinical therapies. It was originally founded as DelMar Pharmaceuticals in 2008 before being renamed Kintara Therapeutics in 2019. The company focuses on developing drugs for the treatment of severe types of cancer such as glioblastoma, a particularly aggressive form of brain tumors. In addition, Kintara Therapeutics also develops clinical therapies for a broader range of indications, including breast cancer and lung cancer. Kintara Therapeutics has developed a proprietary technology platform called VAL-083, which is based on the effect of a chemical compound called dianhydrogalactitol (DAG). VAL-083 is being investigated as a potential treatment for various types of cancer, including those that have become resistant to other therapies. VAL-083 has received orphan drug designation status in the United States and Europe. This means that it is considered a promising new therapy for rare and serious diseases, allowing Kintara Therapeutics to have a faster approval process. In addition to the development of VAL-083, Kintara Therapeutics is also conducting a number of clinical trials on other drug candidates in its pipeline. This includes REM-001, a novel photoimmunotherapy drug for the treatment of cutaneous T-cell lymphomas. REM-001 is based on the use of light and a special type of antibodies to selectively destroy cancer cells. Another important area of business for Kintara Therapeutics is academic collaboration. The company works closely with academic institutions such as the Mayo Clinic, Duke University, and the University of California (San Francisco) to develop and test potential therapies. In addition, Kintara Therapeutics has also partnered with IQVIA, a leading provider of clinical study services, in order to achieve optimal results. In addition to the development and commercialization of cancer drugs, Kintara Therapeutics is also committed to responsible corporate governance. The company is dedicated to having a positive impact on patients, healthcare, and society as a whole through its products and business practices. Overall, Kintara Therapeutics has established a reputation as a reliable partner for the development of cancer therapies and other clinical therapies. The company has a strong portfolio of drug candidates and a broad base for collaborations to unleash its potential in healthcare. Kintara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Kintara Therapeutics's Debt Structure

Kintara Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Kintara Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Kintara Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Kintara Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Kintara Therapeutics stock

What is the debt of Kintara Therapeutics this year?

Kintara Therapeutics has a debt level of -4.91 USD this year.

What was the debt of Kintara Therapeutics compared to the previous year?

The debt of Kintara Therapeutics has increased by -58.33% compared to the previous year dropped.

What are the consequences of high debt for investors in Kintara Therapeutics?

High debt can pose a risk for investors of Kintara Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Kintara Therapeutics?

Low debt means that Kintara Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Kintara Therapeutics affect the company?

An increase in debt of Kintara Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Kintara Therapeutics affect the company?

A reduction in debt of Kintara Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Kintara Therapeutics?

Some factors that can influence the debt of Kintara Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Kintara Therapeutics so important for investors?

The debts of Kintara Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Kintara Therapeutics take to change the debt?

To change the debt, Kintara Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Kintara Therapeutics pay?

Over the past 12 months, Kintara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kintara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Kintara Therapeutics?

The current dividend yield of Kintara Therapeutics is .

When does Kintara Therapeutics pay dividends?

Kintara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kintara Therapeutics?

Kintara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Kintara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kintara Therapeutics located?

Kintara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kintara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kintara Therapeutics from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Kintara Therapeutics pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Kintara Therapeutics in the year 2023?

In the year 2023, Kintara Therapeutics distributed 0 USD as dividends.

In which currency does Kintara Therapeutics pay out the dividend?

The dividends of Kintara Therapeutics are distributed in USD.